Weight Reversal Post Tirzepatide Withdrawal

In this week's View, Dr. Eagle looks at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation. He then explores the SURMOUNT-4 study on weight reversal post tirzepatide withdrawal. Finally, Dr. Eagle examines two JACC articles that cover disease monitoring: one tracking the progression of transthyretin amyloid cardiomyopathy (ATTR-CM) and another assessing cardiovascular risks in patients receiving cancer therapy.     Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle looks at the use of PREVENT equations to assess cardiovascular (CV) disease risk and the CREST-2 randomized trials that examined stenting versus endarterectomy for asymptomatic carotid disease. He then explores physician burnout and the use of coaching to help treat it.  Finally, Dr. Eagle explores how clearer, "front of package" food labeling in grocery stores can provide consumers with practical, science-based guidance to improve CV health.     Subscribe to Eagle's Eye View    

In this week's View, Dr. Eagle looks at the potential for electrophysiology (EP) ablation in ambulatory care. He then explores several new studies that reveal the rising rates of heart failure and hypertension. Finally, Dr. Eagle discusses a very important new survey from ACC on the need to improve the professional climate and culture for US cardiologists and trainees.   Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle looks at gastrointestinal bleeding (GIB) after left atrial appendage occlusion (LAAO).  He then explores lifestyle modifications to treat metabolic syndrome.  Finally, Dr. Eagle examines a recent study which found that beta-blockers failed to reduce death, myocardial infarction (MI) or heart failure (HF) in patients with preserved left ventricular ejection fraction (LVEF).   Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in patients with atrial fibrillation (AFib). He then explores VESALIUS-CV, a study on evolocumab versus placebo in patients with atherosclerosis or diabetes and without previous myocardial infarction (MI) or stroke.  Finally, Dr. Eagle discusses the POLY-HF study on the use of a daily polypill that boosts heart function, improves quality of life, and cuts hospitalizations in underserved patients with heart failure with reduced ejection fraction (HFrEF).  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle highlights several trials recently presented at the TCT Conference in San Francisco. The SELUTION DeNovo trial found that use of the sirolimus-eluting balloons with bailout stenting only if necessary was noninferior to routine drug-eluting stent implantation in patients with de novo coronary artery disease. In the ANDES trial, results showed that the use of direct oral anticoagulants after left atrial appendage closure in patients with non-valvular atrial fibrillation was not superior to dual antiplatelet therapy in preventing device-related thrombosis. Finally, Dr. Eagle discusses the PROCTOR study in which percutaneous coronary intervention (PCI) on saphenous vein grafts versus native vessel PCI in post-coronary artery bypass grafting in patients presenting with graft failure.    Subscribe to Eagle's Eye View    

In this week's View, Dr. Eagle looks at a study comparing the use of aspirin and oral anticoagulants versus anticoagulants alone in the treatment of chronic coronary disease (CCD).  He then explores complications after noncardiac surgery and the efficacy of perioperative blood pressure management. Finally, Dr. Eagle discusses FLUNITY-HD, a study comparing high-dose flu vaccines to standard dose vaccines in reducing hospitalizations.  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle looks at the social drivers behind the rise in heart disease mortality in California. He then explores the prevalence of preexisting cardiometabolic comorbidities and cardiovascular disease among pregnant women. Finally, Dr. Eagle discusses a recent prospective cohort study of patients who undergo coronary artery bypass graft (CABG) and experience new-onset atrial fibrillation (AFib), and how the burden after surgery is very low, especially after 30 days.    Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle looks at the potential value of sodium-glucose cotransporter 2 (SGLT2) agents after transcatheter aortic valve implantation (TAVI). He then explores a new randomized trial, HYPERION, focusing on the addition of sotatercept to lower the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses a state-of-the-art review centered around the use of an anti-inflammatory to lessen cardiovascular events and worse outcomes following acute myocardial infarction (AMI).  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD). He then explores left atrial appendage occlusion (LAAO) in patients with prior intracranial hemorrhage or ischemic stroke. Finally, Dr. Eagle discusses the recently released NEWTON-CABG CardioLink-5 trial on the use of evolocumab in the reduction of saphenous vein graft (SVG) disease rates.  Subscribe to Eagle's Eye View